Spasticity Clinical Trial
— TQTOfficial title:
A Partial-Blind, Randomized, Parallel Design Study With a Nested Crossover Comparison to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial
NCT number | NCT01839279 |
Other study ID # | ZAN-QT-1006 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | April 2013 |
Est. completion date | May 2014 |
Verified date | March 2021 |
Source | Acorda Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single-center, partial-blind, randomized, placebo-controlled, parallel design study with a nested crossover comparison to define the ECG effects of tizanidine compared to placebo and the positive control, moxifloxacin, in healthy men and women. The study will be conducted in a Phase 1 unit with sufficient facilities to house subjects as required by the protocol.
Status | Completed |
Enrollment | 136 |
Est. completion date | May 2014 |
Est. primary completion date | February 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Women of childbearing potential should have a negative urine pregnancy test prior to Screening and Day -2 of the trial - All subjects of childbearing potential must practice a highly effective method of birth control excluding oral contraceptives for the duration of the trial and up to 3 months after the last dose of investigational product. Oral contraceptives are not allowed, based on the precaution listed in the Zanaflex package insert. - Have a body mass index (BMI) ranging between 19 and 30 kg/m2 - Comprehend and be able to provide written informed consent - Be willing and able to comply with all trial requirements Exclusion Criteria: - Female who is either pregnant, breastfeeding or planning to become pregnant - History of hypersensitivity or allergic reaction to tizanidine or moxifloxacin or any of the tablet components - Any condition possibly affecting drug absorption, metabolism or excretion including previous surgery for removal of parts of stomach, bowel, liver, gall bladder, or pancreas - History of Long QT Syndrome or a first-generation relative with this condition - Evidence or history of clinically significant allergies except for untreated, asymptomatic, seasonal allergies at time of dosing, hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, renal, psychiatric, or neurological disease. Determination of clinical significance is to be made at the Investigator's discretion - History or presence of any malignant or benign neoplasm considered by the investigator to be clinically significant - History of drug or alcohol abuse or dependence within the last year - Have an active infectious disease |
Country | Name | City | State |
---|---|---|---|
United States | Covance- Dallas | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
Acorda Therapeutics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Primary Endpoint Will be the Baseline-adjusted, Placebo-corrected Effect on QTc (??QTc) on Day 14. | Change from baseline in Cardiac Repolarization (QTc Interval) at Day 14 (Tizanidine 24 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study. | Baseline and Day 14 | |
Secondary | The Baseline-adjusted, Placebo-corrected (??QTc) on QTc Method Not Selected as Primary Endpoint. | Change from baseline in Cardiac Repolarization (QTc Interval) at Day 5 (Tizanidine 8 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study. | Baseline and Day 5 | |
Secondary | Assessing the Relationship Between Changes in the QTc Interval and Plasma Levels of Tizanidine Using Concentration-effect Modeling | The relationship will be quantified using a linear mixed effects model with an intercept. Data from Day 5 and Day 14 were fitted into regression model to obtain a slope of change. The measure type 'Number' followed by (90% Confidence Interval) shown in results is the slope from the linear fit. | Day 5, Day 14 | |
Secondary | Maximum Plasma Concentration (Cmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State. | 0.5, 1, 1.5, 2, 4, 8, 12 & 24 hours post dose on Days 5 (8 mg) and 14 (24 mg) | ||
Secondary | Time to Reach Maximum Plasma Concentration (Tmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State. | 0.5, 1, 1.5, 2, 4, 8, 12 & 24 hours post dose on Days 5 (8 mg) and 14 (24 mg) | ||
Secondary | Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCt) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State. | 0.5, 1, 1.5, 2, 4, 8, 12 & 24 hours post dose on Days 5 (8 mg) and 14 (24 mg) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06150729 -
Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
|
||
Completed |
NCT02400619 -
Shockwaves Therapy and Botulinum Toxin for the Treatment of Spasticity in Patients With Cerebral Palsy. A Cross Over RCT
|
Phase 1 | |
Completed |
NCT01945684 -
A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity
|
Phase 3 | |
Completed |
NCT02261142 -
Efficacy and Cost-effectiveness of Spasticity Treatment With Multifocal TENS
|
N/A | |
Completed |
NCT01444794 -
Adult Subjects Suffering From Lower Limb Spasticity Following Stroke
|
||
Terminated |
NCT02877836 -
Functional MRI and DTI in the Preoperative Assessment of Dystonia
|
N/A | |
Completed |
NCT02334683 -
Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia
|
N/A | |
Completed |
NCT02170779 -
Developing and Testing a Comprehensive MS Spasticity Management Program
|
Phase 2 | |
Recruiting |
NCT05674604 -
Cryoneurolysis for Knee and Shoulder Pain in an Inpatient Setting
|
||
Not yet recruiting |
NCT05926596 -
Leg Stretching Using an Exoskeleton on Demand for People With Spasticity
|
N/A | |
Terminated |
NCT01712087 -
Long-term Surveillance of the MedStream Programmable Infusion System
|
||
Completed |
NCT03906305 -
Dry Needling and Bobath Treatment Clinical Effects Focused on Stroke Patients
|
N/A | |
Completed |
NCT03302741 -
Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings
|
Phase 4 | |
Completed |
NCT02291159 -
Effects of DNHS Technique in the Treatment of Upper Limb Spasticity and Function in Stroke
|
N/A | |
Completed |
NCT01743651 -
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
|
Phase 3 | |
Completed |
NCT01523210 -
DTI Study of the Influence of Physiotherapy on Distribution of BoNT in Spastic Muscle
|
N/A | |
Completed |
NCT02073513 -
Kinesiotaping the Hand in Cerebral Palsy
|
N/A | |
Completed |
NCT00607542 -
Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity
|
Phase 1/Phase 2 | |
Completed |
NCT00702468 -
Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
|
Phase 3 | |
Active, not recruiting |
NCT04815967 -
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
|
Phase 2/Phase 3 |